Second triMS.online conference

Current concepts in
paediatric MS

Second triMS.online conference, June 2019

The latest research and clinical insights on the theme Current concepts in paediatric MS
An expert panel discussion on a current controversy ‘Clinical trials in paediatric MS should be conducted for study drugs with established efficacy in adult MS’

Novartis

About this event

The second of our triMS.online global conferences took place on 11 June 2019 and showcased the latest insights on the theme: Current concepts in paediatric MS. The second triMS.online conference offered a diverse mix of presentations and engaging discussion on the ‘hot topic’ debate on the motion ‘Clinical trials in paediatric MS should be conducted for study drugs with efficacy in adult MS’.

The conference theme chosen by the Scientific Steering Committee brought paediatric MS to the forefront, enabling participants to gain further knowledge and ask questions to leading experts in the field.

We are committed to ensuring that our conferences are inclusive for all those involved in the study and treatment of MS. We also ensure the content of our conferences are available post-meeting to continue discussion and share information on these important topics.

Video

Chapters

00:03:59	Introduction Chairs: Reem Bunyan, KSA, and Brenda Banwell, USA
00:09:51	Keynote Presentation : Anti-MOG antibodies and their implication for care of children with demyelinatio Yael Hacohen, UK
00:27:41	Q&A: Diagnosis and differential diagnosis of paediatric MS Cheryl Hemingway, UK
00:39:10	Risk factors for paediatric MS Jennifer Graves, USA
00:57:06	Cognitive impairment in paediatric MS Maria Pia Amato, Italy
01:02:57	Keynote presentation: Management of paediatric MS Tanuja Chitnis, USA
01:27:50	Q&A: Company-sponsored satellite: Novartis Pharma AG: Challenges and future outlook for management of paediatric-onset MS Cheryl Hemingway, UK
01:46:49	Current Controversy: ‘Clinical trials in paediatric MS should be conducted for study drugs with established efficacy in adult MS’: Moderator’s introduction and audience vote, position statements, expert panel discussion. Gavin Giovannoni, UK - expert panel:Brenda Banwell, USA, Reem Bunyan, KSA, Tanuja Chitnis, USA, and Saúl Reyes, Colombia
02:18:19	Summing up: Conclusion and thanks Chairs: Reem Bunyan, KSA, and Brenda Banwell, USA
02:31:24	Meeting close Chairs: Reem Bunyan, KSA, and Brenda Banwell, USA

Scientific programme

13:30	Conference open Free time to explore the exhibit and poster halls
14:00	Introduction Chairs: Reem Bunyan, KSA, and Brenda Banwell, USA
14:05	Keynote presentation Anti-MOG antibodies and their implication for care of children with demyelinatio Yael Hacohen, UK Q&A
14:20	Diagnosis and differential diagnosis of paediatric MS Cheryl Hemingway, UK
14:30	Risk factors for paediatric MS Jennifer Graves, USA Q&A
14:40	Cognitive impairment in paediatric MS Maria Pia Amato, Italy
14:50	Keynote presentation Management of paediatric MS Tanuja Chitnis, USA Q&A
15:05	Break Free time to explore the exhibit and poster halls
15:15	Company-sponsored satellite Novartis Pharma AG Challenges and future outlook for management of paediatric-onset MS Cheryl Hemingway, UK
15:35	Current controversy ‘Clinical trials in paediatric MS should be conducted for study drugs with established efficacy in adult MS’ Moderator’s introduction and audience vote Gavin Giovannoni, UK Position statements For: Saúl Reyes, Colombia Against: Reem Bunyan, KSA Expert panel discussion Brenda Banwell, USA, Reem Bunyan, KSA, Tanuja Chitnis, USA, and Saúl Reyes, Colombia Summing up
16:20	Conclusion and thanks Chairs: Reem Bunyan, KSA, and Brenda Banwell, USA
16:30	Meeting close

Resources